Medizinische und gesundheitsökonomische Bedeutung der Messung von Stickstoffmonoxid in der Ausatemluft (FeNO) bei Erwachsenen mit Asthma: Gemeinsames Positionspapier von DGP, BdP, DGAKI und AEDA

Abstract: According to national and international asthma guidelines, FeNO measurement is an indispensable element in the diagnosis and efficient management of asthma. Testing FeNO in a specialist medical care leads to improved treatment of patients with asthma through (1) improved diagnosis of asthma, (2) better control of inhaled therapy, (3) more accurate assessment of adherence, and (4) more precise evaluation of potential biologic therapy. Regular FeNO measurement should therefore be an essential part of specialist care for asthma patients in Germany. Improved asthma management through FeNO measurement also has significant health economic implications as it reduces direct and indirect costs. Reimbursement of FeNO measurement by statutory health insurance (GKV) would therefore not only lead to better care for asthma patients, but also to a reduction in healthcare costs in Germany.